Mss51 deletion enhances muscle metabolism and glucose homeostasis in mice
UMass Chan Affiliations
Division of Endocrinology, Metabolism and Diabetes, Department of MedicineProgram in Molecular Medicine
Document Type
Journal ArticlePublication Date
2019-10-17Keywords
DiabetesFatty acid oxidation
Glucose metabolism
Metabolism
Muscle Biology
Amino Acids, Peptides, and Proteins
Biochemical Phenomena, Metabolism, and Nutrition
Cellular and Molecular Physiology
Endocrinology
Endocrinology, Diabetes, and Metabolism
Hormones, Hormone Substitutes, and Hormone Antagonists
Metadata
Show full item recordAbstract
Myostatin is a negative regulator of muscle growth and metabolism and its inhibition in mice improves insulin sensitivity, increases glucose uptake into skeletal muscle, and decreases total body fat. A recently described mammalian protein called MSS51 is significantly downregulated with myostatin inhibition. In vitro disruption of Mss51 results in increased levels of ATP, beta-oxidation, glycolysis, and oxidative phosphorylation. To determine the in vivo biological function of Mss51 in mice, we disrupted the Mss51 gene by CRISPR/Cas9 and found that Mss51-KO mice have normal muscle weights and fiber-type distribution but reduced fat pads. Myofibers isolated from Mss51-KO mice showed an increased oxygen consumption rate compared with WT controls, indicating an accelerated rate of skeletal muscle metabolism. The expression of genes related to oxidative phosphorylation and fatty acid beta-oxidation were enhanced in skeletal muscle of Mss51-KO mice compared with that of WT mice. We found that mice lacking Mss51 and challenged with a high-fat diet were resistant to diet-induced weight gain, had increased whole-body glucose turnover and glycolysis rate, and increased systemic insulin sensitivity and fatty acid beta-oxidation. These findings demonstrate that MSS51 modulates skeletal muscle mitochondrial respiration and regulates whole-body glucose and fatty acid metabolism, making it a potential target for obesity and diabetes.Source
JCI Insight. 2019 Oct 17;4(20). pii: 122247. doi: 10.1172/jci.insight.122247. Link to article on publisher's site
DOI
10.1172/jci.insight.122247Permanent Link to this Item
http://hdl.handle.net/20.500.14038/41234PubMed ID
31527314Notes
Full author list omitted for brevity. For the full list of authors, see article.
Related Resources
ae974a485f413a2113503eed53cd6c53
10.1172/jci.insight.122247
Scopus Count
Collections
Related items
Showing items related by title, author, creator and subject.
-
Is metabolically healthy obesity really healthyCrawford, Sybil L. (2020-06-01)The concept of metabolically healthy obesity (MHO) – where obesity is not accompanied by cardiometabolic abnormalities such as impaired glucose tolerance – is subject to some controversy. In particular, there is debate regarding whether MHO is benign in the sense that risks of cardiovascular disease (CVD) and metabolic conditions such as diabetes mellitus (DM) are not elevated despite obesity. A number of recent studies suggest, however, that MHO conveys an intermediate risk for cardiometabolic disease, that is, lower than that for metabolically unhealthy obesity (MUHO) but higher than that for metabolically healthy normal weight (MHN). In the current issue of Menopause, Hsu et al present consistent results regarding incidence of DM in analyses of data from postmenopausal women, an understudied group, in the Women’s Health Initiative.
-
A big-data approach to understanding metabolic rate and response to obesity in laboratory mice [preprint]Corrigan, June K.; Ramachandran, Deepti; He, Yuchen; Palmer, Colin; Jurczak, Michael J.; Li, Bingshan; Friedline, Randall H.; Kim, Jason K.; Ramsey, Jon J.; Lantier, Louise; et al. (2019-11-12)Maintaining a healthy body weight requires an exquisite balance between energy intake and energy expenditure. In humans and in laboratory mice these factors are experimentally measured by powerful and sensitive indirect calorimetry devices. To understand the genetic and environmental factors that contribute to the regulation of body weight, an important first step is to establish the normal range of metabolic values and primary sources contributing to variability in results. Here we examine indirect calorimetry results from two experimental mouse projects, the Mouse Metabolic Phenotyping Centers and International Mouse Phenotyping Consortium to develop insights into large-scale trends in mammalian metabolism. Analysis of nearly 10,000 wildtype mice revealed that the largest experimental variances are consequences of institutional site. This institutional effect on variation eclipsed those of housing temperature, body mass, locomotor activity, sex, or season. We do not find support for the claim that female mice have greater metabolic variation than male mice. An analysis of these factors shows a normal distribution for energy expenditure in the phenotypic analysis of 2,246 knockout strains and establishes a reference for the magnitude of metabolic changes. Using this framework, we examine knockout strains with known metabolic phenotypes. We compare these effects with common environmental challenges including age, and exercise. We further examine the distribution of metabolic phenotypes exhibited by knockout strains of genes corresponding to GWAS obesity susceptibility loci. Based on these findings, we provide suggestions for how best to design and conduct energy balance experiments in rodents, as well as how to analyze and report data from these studies. These recommendations will move us closer to the goal of a centralized physiological repository to foster transparency, rigor and reproducibility in metabolic physiology experimentation. -
Endothelial Driven Inflammation in Metabolic Disease: A DissertationMatevossian, Anouch (2015-02-25)Obesity has been on the rise over the last 30 years, reaching worldwide epidemic proportions. Obesity has been linked to multiple metabolic disorders and co-morbidities such as Type 2 Diabetes Mellitus (T2DM), cardiovascular disease, non-alcoholic steatohepatitis and various cancers. Furthermore, obesity is associated with a chronic state of low-grade inflammation in adipose tissue (AT), and it is thought that insulin resistance (IR) and T2DM is associated with the inflammatory state of AT. Endothelial cells (ECs) mediate the migration of immune cells into underlying tissues during times of inflammation, including obesity- and cardiovascular disease-associated inflammation. Cytokines and chemoattractants released from inflamed tissues promote EC activation. Upon activation, ECs increase the expression of leukocyte adhesion molecules (LCAMs) including intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), E-selectin (E-sel) and P-selectin (P-sel). Increased expression of these LCAMs and increased infiltration of inflammatory cells such as macrophages, have been linked to IR, diabetes and atherosclerosis in obese individuals. Preliminary data from our lab suggests that lipolysis induced by the β-adrenergic receptor agonist CL 316,243 causes an increase in endothelial LCAM gene expression. In addition, histological analyses show increased content of immune cells within AT after the ECs become activated. Here, we demonstrate that CL 316,243-induced lipolysis causes infiltration of neutrophils in wild type (WT) but not E-sel knockout (KO) mice. Following EC activation, there was also a marked increase in cytokine gene expression including IL-1β, MCP-1, and TNF-α in an E-sel-dependent manner. In contrast, fasting-induced lipolysis was associated with increased macrophage infiltration into AT in the absence of EC activation in an E-sel-independent manner. We also examined the role of mitogen activated protein kinase kinase kinase kinase 4 (MAP4K4) as a potential contributor to endothelial activation and atherosclerosis. Here we demonstrate that deletion of MAP4K4 in ECs in vitro diminishes TNF-α-induced EC activation. Additionally, MAP4K4 depletion in primary ECs derived from lungs of mice expressing MAP4K4 shRNA decreases EC activation. Finally, endothelial specific depletion or loss of MAP4K4 reduced atherosclerotic plaque formation in vivo. Taken together, these results highlight the importance of the endothelium in modulating obesity-associated comorbidities. Furthermore, these data implicate endothelial MAP4K4 as a novel regulator of EC activation and consequently AT inflammation and atherosclerosis.
